Peroxisome Proliferator-Activated Receptors (PPARs) Antagonists
Categories: “Other Disorders” “Cancer Therapeutics“
Reference #: 2011-004
OTC Contact: Ruchika Nijhara, PhD, MBA, CLP Office: (202) 687-3721 (Directory Information | Send a Message)
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate glucose, lipid, and cholesterol metabolism in response to fatty acids and their derivatives. The present invention encompasses a new class of small molecules that may serve as antagonists of PPARs.
The novel molecules have potential to be used as therapeutics for diabetes, obesity, metabolic syndrome, impaired glucose tolerance, syndrome X, cancer and cardiovascular disease.
- A fluorescent label allows these compounds to be used as both a therapeutic to treat a disease and a diagnostic to detect diseased cells and monitor treatment.
- Selective PPAR gamma, alpha and delta PPAR antagonists
Stage of Development
The inventors have designed and synthesized selective PPAR antagonists and tested their ability to inhibit activation of each PPAR biologically.
Manuscript in preparation
Patent protection sought.